IL260450B - שימוש בגואיאקול למניעה וטיפול במחלת אגירת גליקוגן - Google Patents

שימוש בגואיאקול למניעה וטיפול במחלת אגירת גליקוגן

Info

Publication number
IL260450B
IL260450B IL260450A IL26045018A IL260450B IL 260450 B IL260450 B IL 260450B IL 260450 A IL260450 A IL 260450A IL 26045018 A IL26045018 A IL 26045018A IL 260450 B IL260450 B IL 260450B
Authority
IL
Israel
Prior art keywords
guaiacol
polyglucosan
glycogen
accumulation
cells
Prior art date
Application number
IL260450A
Other languages
English (en)
Inventor
Hasan Orhan Akman
Salvatore Dimauro
Or Kakhlon
Weil Miguel
Original Assignee
Univ Columbia
Hadasit Med Res Service
Univ Ramot
Hasan Orhan Akman
Salvatore Dimauro
Or Kakhlon
Weil Miguel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia, Hadasit Med Res Service, Univ Ramot, Hasan Orhan Akman, Salvatore Dimauro, Or Kakhlon, Weil Miguel filed Critical Univ Columbia
Publication of IL260450B publication Critical patent/IL260450B/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/48—Reserve carbohydrates, e.g. glycogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL260450A 2016-01-06 2017-01-06 שימוש בגואיאקול למניעה וטיפול במחלת אגירת גליקוגן IL260450B (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662275471P 2016-01-06 2016-01-06
PCT/US2017/012455 WO2017120420A1 (en) 2016-01-06 2017-01-06 The use of guaiacol for the prevention and treatment of glycogen storage disease

Publications (1)

Publication Number Publication Date
IL260450B true IL260450B (he) 2022-06-01

Family

ID=59274197

Family Applications (1)

Application Number Title Priority Date Filing Date
IL260450A IL260450B (he) 2016-01-06 2017-01-06 שימוש בגואיאקול למניעה וטיפול במחלת אגירת גליקוגן

Country Status (7)

Country Link
US (1) US10933031B2 (he)
EP (1) EP3400025B1 (he)
ES (1) ES2979171T3 (he)
HU (1) HUE066497T2 (he)
IL (1) IL260450B (he)
PL (1) PL3400025T3 (he)
WO (1) WO2017120420A1 (he)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3866794B1 (en) * 2018-10-17 2024-12-04 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
US11712432B2 (en) * 2018-12-20 2023-08-01 University Of Kentucky Research Foundation Method of treating cancer with an elevated glycogen content
WO2021183554A1 (en) * 2020-03-09 2021-09-16 University Of Kentucky Research Foundation Manipulating glycogen in alzheimer's disease, epilepsy, traumatic brain injury, and als as a treatment
CN120919090B (zh) * 2025-10-16 2025-12-23 山东第一医科大学附属省立医院(山东省立医院) 愈创木酚或其衍生物在制备预防或治疗代谢综合征药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06199695A (ja) 1992-03-06 1994-07-19 Yunie:Kk 糖尿病改善治療剤
GB0308952D0 (en) * 2003-04-17 2003-05-28 St Georges Entpr Ltd Method
WO2005044247A1 (en) 2003-11-07 2005-05-19 Oaky Natural Co., Ltd Pharmaceutical composition containing guaiacol derivatives and syringol derivatives extracted from natural plant vinegar
EP2132309A4 (en) * 2007-02-23 2011-01-05 Univ Florida COMPOSITIONS AND METHODS OF TREATING GLYCOLOGICAL MEMORY DISEASES
EP2155197A4 (en) 2007-03-09 2011-10-12 Link Medicine Corp TREATMENT OF LYSOSOMAL STORAGE DISEASES
US8679478B2 (en) * 2010-10-04 2014-03-25 Duke University Methods of lysosomal storage disease therapy
WO2016090001A1 (en) 2014-12-02 2016-06-09 The Trustees Of Columbia University In The City Of New York Deep intronic mutation found adult polyglucosan body disease and uses thereof
WO2016161086A1 (en) * 2015-03-31 2016-10-06 Duke University Methods and compositions for treating glycogen storage diseases using agents that mimic or elevate cyclic amp

Also Published As

Publication number Publication date
PL3400025T3 (pl) 2024-06-24
US20190015355A1 (en) 2019-01-17
EP3400025A4 (en) 2019-12-11
EP3400025B1 (en) 2024-03-13
EP3400025C0 (en) 2024-03-13
HUE066497T2 (hu) 2024-08-28
ES2979171T3 (es) 2024-09-24
EP3400025A1 (en) 2018-11-14
US10933031B2 (en) 2021-03-02
WO2017120420A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
Pickrell et al. The striatum is highly susceptible to mitochondrial oxidative phosphorylation dysfunctions
Shedlovsky et al. Mouse models of human phenylketonuria
Joshi et al. Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis
US10933031B2 (en) Use of guaiacol for the prevention and treatment of glycogen storage disease
Ji et al. Liver‐specific loss of glucose‐regulated protein 78 perturbs the unfolded protein response and exacerbates a spectrum of liver diseases in mice
Moseley et al. Deficiency in Na, K-ATPase α isoform genes alters spatial learning, motor activity, and anxiety in mice
Sugaya et al. Septo-hippocampal cholinergic and neurotrophin markers in age-induced cognitive decline
Bak et al. Prolonged fasting-induced metabolic signatures in human skeletal muscle of lean and obese men
Kataoka et al. A single amino acid mutation in SNAP-25 induces anxiety-related behavior in mouse
Deignan et al. Contrasting features of urea cycle disorders in human patients and knockout mouse models
Qin et al. Accelerated protein damage in brains of PIMT+/− mice; a possible model for the variability of cognitive decline in human aging
Gao et al. ALG13 deficiency associated with increased seizure susceptibility and severity
Long et al. Global liver proteome analysis using iTRAQ reveals AMPK–mTOR–autophagy signaling is altered by intrauterine growth restriction in newborn piglets
Stokes et al. Mechanisms underlying neonate-specific metabolic effects of volatile anesthetics
Ellis‐Hutchings et al. Whole embryo culture: a “New” technique that enabled decades of mechanistic discoveries
Keller et al. What the BTBR/J mouse has taught us about diabetes and diabetic complications
Yan et al. Klotho downregulation contributes to myocardial damage of cardiorenal syndrome in sepsis
Akai et al. Partial limitation of cellular functions and compensatory modulation of unfolded protein response pathways caused by double-knockout of ATF6α and ATF6β
CA2741664A1 (en) Method for selective control of helper t cell function
JP2003515532A (ja) イノシトールポリリン酸５−ホスファターゼｓｈｉｐ２分子の阻害剤
US20170307636A1 (en) Biomarker for determining mitochondrial damage in friedreich's ataxia
JP2023534878A (ja) ミトコンドリア複合体ｉ欠損症に関連するミトコンドリア疾患又は機能障害の処置のためのアルベリン又はその誘導体の使用
Cunningham et al. Developmental expression pattern of the cholesterogenic enzyme NSDHL and negative selection of NSDHL-deficient cells in the heterozygous Bpa1H/+ mouse
Nyhan et al. 3-Hydroxy-3-methylglutarylCoA lyase deficiency
Ohtsubo Targeted genetic inactivation of N-Acetylglucosaminyltransferase-IVa impairs insulin secretion from pancreatic β cells and evokes type 2 diabetes